Walgreens Outlook Improves As Buyout Faces Shareholder Vote Next Month

Walgreens Boots Alliance reported a better-than-expected fiscal third-quarter net loss of $175 million, with total sales up 7% to $39 billion and improved operating losses in its U.S. Healthcare segment, while also generating positive free cash flow. The company's impending $10 billion acquisition by Sycamore Partners for $11.45 per share, expected to close in Q3/Q4 2025, is viewed as a critical step to accelerate cost-cutting and facilitate a strategic reinvention away from public market pressures, building on ongoing store closures and cost-saving initiatives.

Analysis

Walgreens Boots Alliance (WBA) reported fiscal third-quarter results that signal early signs of a financial stabilization ahead of its proposed acquisition by Sycamore Partners. Although the company posted a net loss of $175 million, or 20 cents per share, this was an improvement over the $2.8 billion loss in the prior quarter and was viewed as better than expected by analysts. Top-line growth remains robust with a 7% increase in total sales to $39 billion. Critically, the U.S. Healthcare segment demonstrated a significant reduction in its operating loss, which narrowed to $64 million from $220 million in the year-ago period, driven by improved contributions from its VillageMD risk-based business. Another key positive highlighted by analysts was the return to positive free cash flow, reversing a recent negative trend. This operational progress provides a stronger foundation for the impending $10 billion buyout by Sycamore Partners at $11.45 per share, which is expected to close in Q3 or Q4 of calendar year 2025. The deal, which also includes a contingent value right of up to $3 per share tied to the future monetization of healthcare assets, is positioned as a strategic reset, allowing WBA to accelerate cost-cutting and restructuring, such as its plan to close 1,200 stores, away from the pressures of public market quarterly reporting.

Key Decisions for Investors

• Given the acquisition offer of $11.45 per share, investors should evaluate the potential merger arbitrage spread against the long closing timeline of Q3/Q4 2025 and associated deal risks, noting the current lack of significant shareholder opposition.
• The contingent value right (CVR) offering up to $3 per share represents a key variable in total shareholder return, warranting a thorough assessment of the probability and potential timing of the monetization of WBA's VillageMD and other healthcare assets.
• Investors should monitor the company's ability to maintain positive free cash flow and continue narrowing losses in its U.S. Healthcare segment as key performance indicators of the turnaround's traction ahead of the acquisition's close.